Author: BEF

SOURCE: VERTEX Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with...